Folgen
Janos Fekete
Janos Fekete
Semmelweis University, Budapest, Hungary
Bestätigte E-Mail-Adresse bei semmelweis.hu
Titel
Zitiert von
Zitiert von
Jahr
ROCplot. org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti‐HER2 therapy using transcriptomic data of 3,104 breast cancer patients
JT Fekete, B Győrffy
International journal of cancer 145 (11), 3140-3151, 2019
2332019
Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients
JT Fekete, Á Ősz, I Pete, GR Nagy, I Vereczkey, B Győrffy
Gynecologic oncology 156 (3), 654-661, 2020
572020
Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030
O Menyhárt, JT Fekete, B Győrffy
Clinical Epidemiology, 1093-1108, 2018
432018
A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors
J Pérez-Pena, J Tibor Fekete, R Páez, M Baliu-Piqué, JÁ García-Saenz, ...
Frontiers in immunology 10, 2802, 2019
292019
Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies
O Menyhárt, JT Fekete, B Győrffy
Carcinogenesis 42 (6), 804-813, 2021
222021
Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors
SA Kovács, JT Fekete, B Győrffy
Acta Pharmacologica Sinica 44 (9), 1879-1889, 2023
212023
Gene expression indicates altered immune modulation and signaling pathway activation in ovarian cancer patients resistant to topotecan
O Menyhárt, JT Fekete, B Győrffy
International Journal of Molecular Sciences 20 (11), 2750, 2019
202019
A unified platform enabling biomarker ranking and validation for 1562 drugs using transcriptomic data of 1250 cancer cell lines
JT Fekete, B Győrffy
Computational and Structural Biotechnology Journal 20, 2885-2894, 2022
122022
Co-transmission of alpha-synuclein and TPPP/p25 inhibits their proteolytic degradation in human cell models
A Lehotzky, J Oláh, JT Fekete, T Szénási, E Szabó, B Győrffy, G Várady, ...
Frontiers in molecular biosciences 8, 666026, 2021
112021
miRNA expression signatures of therapy response in squamous cell carcinomas
JT Fekete, Á Welker, B Győrffy
Cancers 13 (1), 63, 2020
82020
Large-Scale Plasma Proteome Epitome Profiling is an Efficient Tool for the Discovery of Cancer Biomarkers
J Lazar, P Antal-Szalmas, I Kurucz, A Ferenczi, M Jozsi, I Tornyi, M Muller, ...
Molecular & Cellular Proteomics 22 (7), 2023
42023
New transcriptomic biomarkers of 5-fluorouracil resistance
JT Fekete, B Győrffy
International Journal of Molecular Sciences 24 (2), 1508, 2023
32023
Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma
K Mangó, F Fekete, ÁF Kiss, R Erdős, JT Fekete, T Bűdi, E Bruckner, ...
Scientific Reports 13 (1), 11770, 2023
12023
Resistance to Combined Anthracycline–Taxane Chemotherapy Is Associated with Altered Metabolism and Inflammation in Breast Carcinomas
O Menyhárt, JT Fekete, B Győrffy
International Journal of Molecular Sciences 25 (2), 1063, 2024
2024
Increased activity of inflammation-related signaling pathways in anthracycline-paclitaxel resistant breast carcinomas
O Menyhárt, TJ Fekete, B Győrffy
Magyar Onkologia 67 (3), 203-212, 2023
2023
Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination
T Resál, P Bacsur, M Horváth, K Szántó, M Rutka, A Bálint, A Fábián, ...
Therapeutic Advances in Gastroenterology 16, 17562848231183529, 2023
2023
Prediktív biomarkerek vizsgálata különböző daganattípusokban
JT Fekete
2022
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–17